Co-pay accumulator adjustment programs can have different effects for individuals with varying health plan types or income levels, explained Bruce Sherman, MD, chief medical officer of the National Alliance of Healthcare Purchaser Coalitions.
Co-pay accumulator adjustment programs can have different effects for individuals with varying health plan types or income levels, explained Bruce Sherman, MD, chief medical officer of the National Alliance of Healthcare Purchaser Coalitions.
Transcript
How might co-pay accumulator adjustment programs disproportionately affect certain populations?
From an insurance standpoint, the co-pay accumulator programs really are only in effect for individuals enrolled in a high-deductible, consumer-directed health plan. So, individuals who are in PPO [preferred provider organization] plans typically don’t have the high deductible with the pharmacy benefit that individuals have who are enrolled in a high-deductible health plan, where typically the deductible is a combined medical and pharmacy benefit.
That’s one consideration; the other concern is income, and the fact that there’s some evidence to suggest that low-income individuals, who are more price-sensitive to access to and use of healthcare, might preferentially select a high-deductible health plan simply because it provides them with more money in their pocket because of lower premiums, but at the expense of a high deductible. And they are probably the ones who would be at greatest risk of discontinuation of medication when faced with this so-called “co-pay surprise” when they’ve maximized the value derived from their co-pay support but haven’t yet met their deductible because of the co-pay accumulator adjustment program.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen